SOURCE: Rheologics Technologies, Inc.

October 09, 2006 10:10 ET

Rheologics Adds Sales and Marketing Veteran to Management Team

EXTON, PA -- (MARKET WIRE) -- October 9, 2006 -- Rheologics, Inc., a subsidiary of Rheologics Technologies, Inc. (PINKSHEETS: RTGI), ("Rheologics", the "Company"), the leader in the study of blood viscosity and its relationship to cardiovascular disease, is pleased to announce that Mr. William Meinel has joined the Company as Vice President of Sales and Marketing. The addition of Mr. Meinel occurs in parallel with a drive by the Company to concentrate its resources around the commercialization of its proprietary medical device and diagnostic technologies.

Mr. Meinel brings to Rheologics over 20 years of experience in marketing and is charged with helping the Company create a sales and marketing program to further develop brand awareness and brand recognition.

Previously, Mr. Meinel has served as Group Director of Corporate Branding, LLC (CoreBrand), one of the leading brand strategy firms in the U.S. and as a principal in his own marketing firm, where he developed and executed marketing platforms for a broad range of organizations, including Glaxo, DuPont, SONY, Sharp, New York Life, ExxonMobil and the University of Pennsylvania. Prior to joining Rheologics, Mr. Meinel was VP of Brand Development at ARAMARK where he was responsible for implementation of corporate branding and marketing policy across multiple lines of business.

In addition, Rheologics has accepted the resignation of Dr. Ralph Holsworth, former Vice President of Pharmaceuticals and member of Rheologics' managing director team. Dr. Holsworth is leaving Rheologics to pursue other interests. Rheologics would like to thank him for his contributions and wishes him success in his future endeavors.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventative diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.

Contact Information